#1 Clinical Trials Search in Europe

Dermatophagoides Pteronyssinus Extract

This article discusses clinical trials investigating the use of Dermatophagoides Pteronyssinus Extract, a substance derived from house dust mites, in the treatment of allergies. These trials aim to evaluate the safety and effectiveness of various immunotherapy approaches using this extract for patients with allergic conditions such as rhinitis, rhinoconjunctivitis, and asthma.

Table of Contents

What is DERMATOPHAGOIDES PTERONYSSINUS EXTRACT?

DERMATOPHAGOIDES PTERONYSSINUS EXTRACT is a medical product derived from house dust mites, specifically the species Dermatophagoides pteronyssinus[1]. This extract is used in both diagnostic and therapeutic applications for allergies related to house dust mites. It’s important to note that this extract is considered a structurally diverse substance – allergen, meaning it contains various components that can trigger allergic responses in sensitive individuals.

What Conditions Does It Treat?

DERMATOPHAGOIDES PTERONYSSINUS EXTRACT is primarily used to diagnose and treat allergic conditions caused by house dust mites. These conditions include:

  • Allergic rhinitis (hay fever): Inflammation of the nasal passages causing symptoms like sneezing, runny nose, and nasal congestion[2]
  • Allergic rhinoconjunctivitis: A condition affecting both the nose and eyes, causing symptoms in both areas[2]
  • Allergic asthma: A type of asthma triggered by allergens, in this case, house dust mites[2]

These conditions can range from moderate to severe and significantly impact a person’s quality of life.

How Does It Work?

DERMATOPHAGOIDES PTERONYSSINUS EXTRACT works through a process called immunotherapy. When used therapeutically, small amounts of the allergen are introduced to the patient’s body, gradually increasing over time. This helps the immune system build tolerance to the allergen, reducing allergic reactions when exposed to house dust mites in everyday life[3].

In diagnostic applications, the extract is used to identify if a person is allergic to house dust mites. This is typically done through skin prick tests or by measuring specific IgE antibodies in the blood[1].

How is It Administered?

DERMATOPHAGOIDES PTERONYSSINUS EXTRACT can be administered in several ways:

  • Skin Prick Test: For diagnostic purposes, a drop of the solution is placed on the skin, which is then pricked. A positive reaction indicates an allergy[1].
  • Sublingual Immunotherapy (SLIT): The extract is placed under the tongue as drops or tablets for treatment purposes[3].
  • Subcutaneous Immunotherapy (SCIT): The extract is injected under the skin in gradually increasing doses[4].

Effectiveness

Clinical trials have shown that immunotherapy with DERMATOPHAGOIDES PTERONYSSINUS EXTRACT can be effective in reducing symptoms of allergic rhinitis, rhinoconjunctivitis, and allergic asthma. The effectiveness is often measured using scales such as the Combined Symptom and Medication Score (CSMS), which takes into account both the severity of symptoms and the need for rescue medication[3].

Potential Side Effects and Safety Considerations

While generally considered safe when used as directed, DERMATOPHAGOIDES PTERONYSSINUS EXTRACT can cause side effects, including:

  • Local reactions at the site of administration (redness, swelling, itching)
  • Mild systemic reactions (sneezing, runny nose)
  • In rare cases, more severe allergic reactions

It’s crucial to use this treatment under medical supervision, especially for individuals with severe asthma or other significant health conditions[4].

Who Can Use This Treatment?

DERMATOPHAGOIDES PTERONYSSINUS EXTRACT is typically used for:

  • Individuals aged 12-65 with confirmed allergy to house dust mites
  • Patients with moderate to severe allergic rhinitis or rhinoconjunctivitis
  • Those with well-controlled mild to moderate allergic asthma

However, it may not be suitable for everyone. Contraindications include severe or uncontrolled asthma, certain immune system disorders, and ongoing treatment with certain medications[3][4].

Current Clinical Trials

Several clinical trials are ongoing to further investigate the efficacy and safety of DERMATOPHAGOIDES PTERONYSSINUS EXTRACT and similar allergen extracts. These studies aim to optimize dosing, evaluate long-term effects, and compare different administration methods. Patients interested in participating in such trials should consult with their healthcare provider for more information[2][3][4].

Aspect Details
Study Type Phase II-III clinical trials
Main Objective Evaluate efficacy and safety of immunotherapy using Dermatophagoides Pteronyssinus Extract
Target Conditions Moderate-to-severe allergic rhinitis/rhinoconjunctivitis, with or without mild-to-moderate controlled asthma
Administration Methods Sublingual immunotherapy, skin-prick tests
Primary Endpoint Combined Symptom and Medication Score (CSMS) during peak allergy periods
Key Inclusion Criteria Adults 18-65, confirmed house dust mite allergy, moderate-to-severe symptoms
Key Exclusion Criteria Recent immunotherapy, severe asthma, certain medical conditions, pregnancy
Safety Assessments Monitoring of adverse events, tolerability of treatment

FAQ

  • What is Dermatophagoides Pteronyssinus Extract? Dermatophagoides Pteronyssinus Extract is a substance derived from house dust mites, specifically the Dermatophagoides pteronyssinus species. It is used in allergy testing and immunotherapy treatments for people allergic to house dust mites.
  • What conditions are being studied using this extract? The clinical trials are studying the use of Dermatophagoides Pteronyssinus Extract in treating conditions such as moderate-to-severe allergic rhinitis, rhinoconjunctivitis, and mild-to-moderate controlled allergic asthma caused by house dust mite allergies.
  • How is the extract administered in these trials? The extract is being studied in various forms of administration, including sublingual immunotherapy (under the tongue) and as a solution for skin-prick tests.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety and efficacy of immunotherapy treatments using Dermatophagoides Pteronyssinus Extract, determine the most effective dosages, and evaluate their impact on allergy symptoms and quality of life for patients.
  • Who can participate in these clinical trials? Participants in these trials are typically adults aged 18-65 with confirmed allergies to house dust mites, experiencing moderate-to-severe allergy symptoms. Specific inclusion and exclusion criteria vary for each trial, considering factors such as medical history, severity of symptoms, and previous treatments.

Ongoing Clinical Trials on Dermatophagoides Pteronyssinus Extract

  • Testing sublingual immunotherapy with dermatophagoides pteronyssinus extract for adults with moderate to severe house dust mite allergy

    Recruiting

    4 1
    Investigated drugs:
    Germany Spain

  • Study on the Effectiveness and Safety of Sublingual MM09 for Patients Aged 12-65 with Allergies to House Dust Mites and Rhinitis/Rhinoconjunctivitis with or without Asthma

    Recruiting

    3 1
    Investigated drugs:
    Portugal Spain

  • Skin Prick Test Diagnostic Accuracy Study in Patients with Dermatophagoides pteronyssinus and Dermatophagoides farinae Allergy Using Dermatophagoides pteronyssinus Extract and Dermatophagoides farinae Extract

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Spain

  • A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of Allergenic Extract of Olea Europaea Pollen for Patients with Moderate-to-Severe Olive Pollen Allergy

    Not recruiting

    4 1 1
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of Phleum Pratense Pollen Extract for Patients with Moderate-to-Severe Grass Pollen Allergy

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness and Safety of Sublingual Immunotherapy with Betula Pendula Pollen Extract for Patients with Birch Pollen Allergy

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Allergen: A substance that can cause an allergic reaction in some people. In this context, it refers to proteins from house dust mites.
  • Dermatophagoides Pteronyssinus: A species of house dust mite that is a common cause of allergies in humans.
  • Immunotherapy: A treatment approach that aims to modify the immune system's response to an allergen, potentially reducing allergy symptoms over time.
  • Rhinitis: Inflammation of the nasal passages, often causing symptoms such as sneezing, runny nose, and congestion.
  • Rhinoconjunctivitis: A condition characterized by inflammation of both the nasal passages and the conjunctiva (the membrane covering the eye), typically causing symptoms in both the nose and eyes.
  • Sublingual: Referring to the area under the tongue. In these trials, it describes a method of administering the allergen extract by placing it under the tongue.
  • CSMS (Combined Symptom and Medication Score): A measure used in allergy studies to assess the severity of symptoms and the need for medication.
  • Skin-prick test: A diagnostic method used to identify specific allergies by observing the skin's reaction to small amounts of potential allergens.
  • FEV1 (Forced Expiratory Volume in 1 second): A measure of lung function, specifically how much air a person can exhale in one second.
  • ARIA (Allergic Rhinitis and its Impact on Asthma): A set of guidelines for diagnosing and managing allergic rhinitis and its impact on asthma.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-immunotherapy-with-betula-pendula-pollen-extract-for-patients-with-birch-pollen-allergy/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-immunotherapy-with-phleum-pratense-pollen-extract-for-patients-with-moderate-to-severe-grass-pollen-allergy/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-mm09-for-patients-aged-12-65-with-allergies-to-house-dust-mites-and-rhinitis-rhinoconjunctivitis-with-or-without-asthma/
  4. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-allergenic-extract-of-olea-europaea-pollen-for-patients-with-moderate-to-severe-olive-pollen-allergy/